User:David Canner/Sandbox HIV: Difference between revisions

Line 6:

===Medical Implications===

There currently is no cure or vaccine against contracting HIV. AIDS researchers, however, have discovered treatments that can slow progression of the HIV virus, thanks in large part to our understanding of the structure of HIV-1 protease. <scene name='User:David_Canner/Sandbox_HIV/Saquinavir/4'>Saquinavir</scene> was the the first protease inhibitor approved by the FDA for the treatment of HIV. It inhibits HIV-1 protease by <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'>binding tightly to the active site tunnel</scene>, preventing nascent peptides from entering and <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/1'>interfering with the catalytic triad</scene>.<ref>PMID:17243183</ref> Saquinavir effectively acts like an uncleavable ligand, highlighted by the protease flaps undergoing <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'>a similar movement</scene> upon binding. Other drugs used to treat patients infected with the HIV virus which inhibit <scene name='User:David_Canner/Sandbox_HIV/Inhibitor_intro/1'>HIV-1 Protease</scene> include <scene name='User:David_Canner/Sandbox_HIV/Indinavir/2'>Indinavir </scene> ([[1hsg]]), <scene name='User:David_Canner/Sandbox_HIV/Ritonavir/1'>Ritonavir</scene> ([[1hxw]]), and Nelfinavir (~~PDB entry~~ [[1ohr]]).

There currently is no cure or vaccine against contracting HIV. AIDS researchers, however, have discovered treatments that can slow progression of the HIV virus, thanks in large part to our understanding of the structure of HIV-1 protease. <scene name='User:David_Canner/Sandbox_HIV/Saquinavir/4'>Saquinavir</scene> was the the first protease inhibitor approved by the FDA for the treatment of HIV. It inhibits HIV-1 protease by <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'>binding tightly to the active site tunnel</scene>, preventing nascent peptides from entering and <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/1'>interfering with the catalytic triad</scene>.<ref>PMID:17243183</ref> Saquinavir effectively acts like an uncleavable ligand, highlighted by the protease flaps undergoing <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'>a similar movement</scene> upon binding. Other drugs used to treat patients infected with the HIV virus which inhibit <scene name='User:David_Canner/Sandbox_HIV/Inhibitor_intro/1'>HIV-1 Protease</scene> include <scene name='User:David_Canner/Sandbox_HIV/Indinavir/2'>Indinavir </scene> ([[1hsg]]), <scene name='User:David_Canner/Sandbox_HIV/Ritonavir/1'>Ritonavir</scene> ([[1hxw]]), and <scene name='User:David_Canner/Sandbox_HIV/Nelfinavir/2'>Nelfinavir</scene> ([[1ohr]]).

__NOEDITSECTION__

__NOTOC__

@@ Line 6: / Line 6: @@
 ===Medical Implications===
-There currently is no cure or vaccine against contracting HIV.  AIDS researchers, however, have discovered treatments that can slow progression of the HIV virus, thanks in large part to our understanding of the structure of HIV-1 protease. <scene name='User:David_Canner/Sandbox_HIV/Saquinavir/4'>Saquinavir</scene> was the the first protease inhibitor approved by the FDA for the treatment of HIV. It inhibits HIV-1 protease by <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'>binding tightly to the active site tunnel</scene>, preventing nascent peptides from entering and <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/1'>interfering with the catalytic triad</scene>.<ref>PMID:17243183</ref> Saquinavir effectively acts like an uncleavable ligand, highlighted by the protease flaps undergoing <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'>a similar movement</scene> upon binding. Other drugs used to treat patients infected with the HIV virus which inhibit <scene name='User:David_Canner/Sandbox_HIV/Inhibitor_intro/1'>HIV-1 Protease</scene> include <scene name='User:David_Canner/Sandbox_HIV/Indinavir/2'>Indinavir </scene> ([[1hsg]]), <scene name='User:David_Canner/Sandbox_HIV/Ritonavir/1'>Ritonavir</scene> ([[1hxw]]), and Nelfinavir (PDB entry [[1ohr]]).
+There currently is no cure or vaccine against contracting HIV.  AIDS researchers, however, have discovered treatments that can slow progression of the HIV virus, thanks in large part to our understanding of the structure of HIV-1 protease. <scene name='User:David_Canner/Sandbox_HIV/Saquinavir/4'>Saquinavir</scene> was the the first protease inhibitor approved by the FDA for the treatment of HIV. It inhibits HIV-1 protease by <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'>binding tightly to the active site tunnel</scene>, preventing nascent peptides from entering and <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/1'>interfering with the catalytic triad</scene>.<ref>PMID:17243183</ref> Saquinavir effectively acts like an uncleavable ligand, highlighted by the protease flaps undergoing <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'>a similar movement</scene> upon binding. Other drugs used to treat patients infected with the HIV virus which inhibit <scene name='User:David_Canner/Sandbox_HIV/Inhibitor_intro/1'>HIV-1 Protease</scene> include <scene name='User:David_Canner/Sandbox_HIV/Indinavir/2'>Indinavir </scene> ([[1hsg]]), <scene name='User:David_Canner/Sandbox_HIV/Ritonavir/1'>Ritonavir</scene> ([[1hxw]]), and <scene name='User:David_Canner/Sandbox_HIV/Nelfinavir/2'>Nelfinavir</scene> ([[1ohr]]).
 __NOEDITSECTION__
 __NOTOC__